MedPath

Ferring Expands Adstiladrin Production Capacity with New Facility in Finland

  • Ferring is expanding its manufacturing capabilities with a new 25,000 square meter facility in Finland to produce the drug substance for Adstiladrin.
  • The expansion follows FDA approval of Ferring's scale-up process in June 2023 and a partnership with SK pharmteco to further increase manufacturing capacity.
  • Adstiladrin, an adenovirus vector-based gene therapy, received FDA approval in 2022 as the first gene therapy for bladder cancer, administered via catheter directly into the bladder.
  • Ferring is also nearing completion of a fill/finish plant in Parsippany, New Jersey, focused on final drug product manufacturing, with larger-scale production expected in the coming years.
Ferring Pharmaceuticals is significantly increasing its production capacity for Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy for bladder cancer, with a new manufacturing facility in Finland. The 25,000 square meter facility will focus on producing the drug substance (DS) for the adenovirus vector-based gene therapy. This expansion follows FDA approval of Ferring's scale-up process in June 2023.

Manufacturing Expansion Details

In addition to the Finland facility, Ferring is nearing completion of a drug product (DP) manufacturing facility at its Parsippany, New Jersey campus. This fill/finish plant will concentrate on final drug product manufacturing. According to a Ferring spokesperson, larger-scale production at the New Jersey site is anticipated to commence within the coming years, pending FDA and other necessary approvals. The new unit will incorporate sustainable energy solutions, including solar energy utilization and waste heat recovery, and the company is applying for LEED environmental certification for its sustainable development.

Adstiladrin's Role in Bladder Cancer Treatment

Adstiladrin, approved by the FDA in 2022, represents a significant advancement as the first gene therapy for bladder cancer. The intravesical, non-replicating gene therapy is administered locally via catheter directly into the bladder every three months. It works by targeting the patient’s own bladder wall cells to enhance the body’s natural defenses against the cancer. Ferring announced full commercial availability of Adstiladrin in the US in January 2024.

Strategic Partnerships and Commitment

Ferring has also partnered with contract development and manufacturing organization (CDMO) SK pharmteco to scale up commercial manufacturing capacity for the DS used in Adstiladrin. This agreement, established in April 2024, includes a technology transfer of the adenoviral vector-based gene therapy DS for the manufacturing process, as well as analytical test methods for release and stability testing.
"The continued investment and expansion of our gene-therapy manufacturing infrastructure reflects Ferring’s strong commitment to deliver end-to-end solutions for even the most highly complex manufacturing challenges as part of our mission to fulfill the unmet clinical needs for people with bladder cancer," said Armin Metzger, chief technical operations officer, Ferring Pharmaceuticals.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cadrenal Therapeutics Plans Phase 3 Trial for Tecarfarin in LVAD Patients

Cadrenal Therapeutics aims to initiate a Phase 3 clinical trial for tecarfarin in LVAD patients in 2025, following discussions with the FDA.

Theradaptive's OsteoAdapt SP Spinal Fusion Trial Expands to ALIF and LLIF Procedures

Theradaptive's OsteoAdapt SP clinical trial expands to include anterior lumbar interbody fusion (ALIF) and lateral lumbar interbody fusion (LLIF) procedures, alongside the existing transforaminal interbody fusion (TLIF) approach.

Endo Receives FDA Approval for Manufacturing Facility in Indore, India

The U.S. Food and Drug Administration (FDA) has approved Endo's manufacturing facility in Indore, India, for commercial production of VASOSTRICT.

Real-World Data and Ongoing Trials Highlight Efficacy of Nadofaragene Firadenovec in Bladder Cancer

Real-world data presented at the 2025 ASCO Genitourinary Cancers Symposium indicates nadofaragene firadenovec demonstrates positive efficacy and safety outcomes in treating NMIBC.

FDA Approves New Intravenous Formulation of Ustekinumab Biosimilar SELARSDI™

The FDA has approved a new intravenous formulation of SELARSDI™ (ustekinumab-aekn), a biosimilar to STELARA® (ustekinumab), expanding its potential use.

FDA Approves New IV Infusion Presentation of Selarsdi (ustekinumab-aekn) Biosimilar

The FDA has approved a new intravenous infusion formulation of Selarsdi (ustekinumab-aekn), a biosimilar to Stelara, expanding its potential use.

FDA Grants Fast Track Designation to Zilganersen for Alexander Disease

The FDA has granted Fast Track designation to zilganersen for treating Alexander disease (AxD), an ultra-rare neurological disorder.

Zilganersen Receives FDA Fast Track Designation for Alexander Disease

The FDA has granted Fast Track designation to zilganersen for treating Alexander Disease (AxD), an ultra-rare and fatal neurological disorder.

Mirdametinib's NDA for NF1-PN Granted Priority Review by FDA

The FDA has granted priority review to SpringWorks Therapeutics' NDA for mirdametinib in treating Neurofibromatosis Type 1-associated plexiform neurofibromas (NF1-PN).

FDA Grants Breakthrough Therapy Designation to Crinecerfont for Congenital Adrenal Hyperplasia

The FDA has granted Breakthrough Therapy designation to crinecerfont for congenital adrenal hyperplasia (CAH), highlighting the significant unmet need for effective treatments.

Reference News

[1]
Ferring bolsters Adstiladrin production with Finland expansion - BioProcess International
bioprocessintl.com · Oct 7, 2024

Ferring's 25,000 sqm facility, approved by FDA in June 2023, produces adenovirus vector-based gene therapy Adstiladrin. ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy